Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development CliCr® can be partnered or licensed as a stand-alone technology Cristal is actively seeking partners for CliCr® for a variety of applications Maastricht, The Netherlands, 29 September 2020 – Cristal Therapeutics, […]

Small publication demonstrates that superior therapeutic profiles of CriPec® nanomedicines result from rational design Maastricht, The Netherlands, 11th May 2020 – Cristal Therapeutics, a Phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces the publication of a paper on its CriPec® nanomedicine technology […]

October 7-8 PODD Boston, USA

September 12-14 EACR: Nanotechnology in Cancer Cambridge, UK

Maastricht, The Netherlands, 1stAugust 2019 – Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces that Dr Werner Cautreels is joining the Company’s supervisory board taking on the role of Chairman. Dr Cautreels succeeds Simon Sturge, who steps down […]